EGFR and metastatic colorectal cancer: Another Phase II study suggested that the combination of erlotinib with irinotecan and the anti-EGFR antibody panitumumab might offer improved efficacy and a good safety profile in metastatic colorectal cancer patients, meriting further investigation [56].